BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

Supernus Pharmaceuticals 

1550 East Gude Drive

Rockville  Maryland  20850  U.S.A.
Phone: 301-838-2501 Fax: n/a


SEARCH JOBS





 Key Statistics


Email:
Ownership: Public

Web Site: Supernus Pharmaceuticals
Employees:
Symbol: SUPN
 



Industry
Pharmaceutical






 Company News
Supernus Pharmaceuticals (SUPN) Announces Fourth Quarter and Full Year 2013 Results 3/13/2014 9:25:16 AM    More...
Supernus Pharmaceuticals (SUPN) Announces Issuance Of Third US Patent Protecting Trokendi XR™ 3/12/2014 9:32:24 AM    More...
Supernus Pharmaceuticals (SUPN) To Host Fourth Quarter And Full Year 2013 Earnings Conference Call 2/25/2014 7:54:15 AM    More...
Supernus Pharmaceuticals (SUPN) To Present At Cowen and Company Healthcare Conference In March 2/20/2014 7:23:01 AM    More...
Supernus Pharmaceuticals (SUPN) At Citibank And RBC Global Healthcare Conferences In February 2/7/2014 6:45:55 AM    More...
Supernus Pharmaceuticals (SUPN) Announces Publication Of Phase III Study (PROSPER) Results On Oxtellar XR® 2/3/2014 8:49:35 AM    More...
Supernus Pharmaceuticals (SUPN) Announces Issuance Of First Use Patents Protecting SPN-812 As A Novel Non-Stimulant ADHD Product 1/27/2014 8:51:05 AM    More...
Supernus Pharmaceuticals (SUPN) Announces Issuance Of Third US Patent Protecting Oxtellar XR® 1/7/2014 9:30:27 AM    More...
Supernus Pharmaceuticals (SUPN) Announces Resignation Of Board Member 12/27/2013 7:28:03 AM    More...
Supernus Pharmaceuticals (SUPN) Announces FDA Approval Of Its Partner's Product, Orenitram™ 12/27/2013 6:49:28 AM    More...
123456